Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
ADX-324: An Investigational siRNA Therapeutic for Hereditary Angioedema
I. Executive Summary
ADX-324 is an investigational short-interfering RNA (siRNA) therapeutic agent under development by ADARx Pharmaceuticals, Inc., primarily for the prophylactic treatment of Hereditary Angioedema (HAE).[1] The therapeutic strategy of ADX-324 centers on the specific targeting and reduction of plasma prekallikrein (PKK) production, a pivotal protein in the pathophysiological cascade leading to bradykinin generation and subsequent angioedema attacks characteristic of HAE. This is achieved through the RNA interference (RNAi) mechanism, where ADX-324 is designed to silence the KLKB1 messenger RNA (mRNA).[2]
A key feature of ADX-324's development is its utilization of ADARx Pharmaceuticals' proprietary RNA targeting platform. This platform incorporates technologies for liver-directed delivery, primarily through N-acetylgalactosamine (GalNAc) conjugation (referred to as PLR™ - Preeminent Liver RNA, or CTD™ - Cell-Targeted Delivery technology), and advanced oligonucleotide optimization strategies (known as SPE™ - Sequence Specific Platform Enhancement, or MST™ - mRNA Silencing Technology) to enhance potency, stability, and duration of action.[1]
Preclinical investigations, notably studies conducted in non-human primates, have provided encouraging data supporting the potential for ADX-324 to be administered via a long-acting, low-volume subcutaneous dosing regimen, possibly on a bi-annual or even annual basis.[1] Such a dosing schedule would represent a significant advancement in convenience and treatment burden reduction for HAE patients. Pharmacodynamic data from these preclinical efforts were presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in November 2023, signaling progress in understanding the drug's activity profile.[8]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/05/07 | Phase 3 | Recruiting | |||
2023/01/20 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.